Company Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
3.28 ^USD	+2.98%		-2.38%	+7.89%

04-04	UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating	MT
04-01	Barclays Raises Price Target on Kodiak Sciences to $3 From $2, Maintains Underweight Rating	MT

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Number of employees: 111

Managers	Title	Age	Since
Victor Perlroth CEO	Chief Executive Officer	51	08-12-31
John Borgeson DFI	Director of Finance/CFO	62	15-12-31
Pablo Velazquez-Martin CTO	Chief Tech/Sci/R&D Officer	-	-
Michael S. Louie CTO	Chief Tech/Sci/R&D Officer	-	22-01-31
Almas Qudrat PRN	Corporate Officer/Principal	-	17-12-31

Members of the board	Title	Age	Since
Felix Baker BRD	Director/Board Member	55	15-08-31
Tai Yin Yang BRD	Director/Board Member	70	19-12-16
Richard Levy BRD	Director/Board Member	66	18-07-17
Robert Profusek BRD	Director/Board Member	73	18-05-31
Bassil Dahiyat BRD	Director/Board Member	53	18-07-17
Victor Perlroth CEO	Chief Executive Officer	51	08-12-31
Charles Bancroft BRD	Director/Board Member	65	20-04-01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	52,534,947	49,562,960 ( 94.34 %)	0	94.34 %

Name	Equities	%	Valuation
Baker Bros. Advisors LP 32.99 %	17,310,490	32.99 %	91 M $
BlackRock Advisors LLC 7.384 %	3,874,713	7.384 %	20 M $
Victor Perlroth 5.136 %	2,695,038	5.136 %	14 M $
Acadian Asset Management LLC 3.637 %	1,908,302	3.637 %	10 M $
Newtyn Management LLC 3.376 %	1,771,241	3.376 %	9 M $
Vanguard Fiduciary Trust Co. 3.132 %	1,643,470	3.132 %	9 M $
D.E. Shaw & Co., Inc. 2.304 %	1,208,973	2.304 %	6 M $
ICONIQ Capital LLC 1.938 %	1,016,864	1.938 %	5 M $
SilverArc Capital Management LLC 1.906 %	1,000,000	1.906 %	5 M $
Jacobs Levy Equity Management, Inc. 1.379 %	723,675	1.379 %	4 M $

Kodiak Sciences, Inc.

1200 Page Mill Road

94304, Palo Alto

+650 281 0850

http://www.kodiak.com

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.28 USD

Average target price

4.25 USD

Spread / Average Target

+29.57%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
KODIAK SCIENCES INC.	+7.89%	172M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs